INNPF - This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain | Benzinga
Innocan Pharma Corporation (CSE:INNO) (FSE: IP4) (OTCQB:INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration (FDA), for its Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.
With the move, the company initiated the regulatory process with the FDA for the approval of its prolonged CBD release technology for human use.
Why It Matters
"Innocan’s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of its LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions," the company said in a press release.
Iris Bincovich, CEO of Innocan, explained what the move means for Innocan.
"This is ...